NeoGenomics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request metadata references 2022 Q4, this is an annual filing and the figures below are primarily full-year comparisons. NeoGenomics provides oncology diagnostic testing and consultative services, as well as testing and research services for pharmaceutical companies. Clinical Services represented 82% of 2022 revenue and Pharma Services 18%.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $509.7 million | $484.3 million | +5.2% |
| Clinical Services revenue | $418.8 million | $404.2 million | +3.6% |
| Pharma Services revenue | $91.0 million | $80.2 million | +13.5% |
| Gross profit / margin | $187.9 million / 36.9% | $187.1 million / 38.6% | Margin down 1.7 percentage points |
| Operating loss | $157.6 million | $118.8 million | Loss increased |
| Net loss | $144.3 million; $1.16 per diluted share | $8.3 million; $0.07 per diluted share | Loss increased substantially |
| Adjusted EBITDA (non-GAAP) | Loss of $48.0 million | Loss of $4.2 million | Loss increased |
| Cash used in operating activities | $66.0 million | $26.7 million | Cash use increased |
At December 31, 2022, cash and cash equivalents were $263.2 million, marketable securities were $174.8 million, and working capital was $515.4 million. Management said cash, marketable securities, and expected collections should fund near-term operating and capital needs for at least 12 months. Convertible notes had a carrying value of $535.3 million; principal was $201.25 million due 2025 and $345.0 million due 2028. The company also reported $75.5 million of operating lease liabilities.
Material changes and unusual items
- Revenue increased in both segments. Pharma Services grew faster, supported by greater testing volume and billings, including RaDaR testing. Clinical Services growth reflected average price, reimbursement initiatives, and test mix; COVID-19 PCR testing revenue ceased after the company exited that business in 2021.
- Gross margin declined, primarily due to higher payroll-related costs and $19.4 million of amortization of acquired Inivata developed technology. Operating expenses rose; 2022 included $4.5 million of restructuring charges and higher research and development spending.
- FY2021 net loss benefited from a $109.3 million gain associated with the Inivata acquisition. No comparable gain was recorded in 2022. The 2022 net loss also reflects substantially higher operating expenses and amortization.
- Operating cash use increased by $39.3 million year over year, reflecting operating results, changes in operating assets and liabilities, and costs supporting growth initiatives. Cash and cash equivalents fell by $53.6 million during 2022.
- Management began a restructuring program in 2022 to improve execution and efficiency. It expects approximately $5.0 million of additional restructuring charges in 2023 and expects the program to be completed by December 31, 2023.
Outlook, risks, and contingencies
Management’s 2023 priorities include profitable growth in the core business, increasing NGS mix and volume, improving turnaround time and efficiency, launching RaDaR for clinical use and a new Neo Comprehensive NGS offering, and improving Pharma growth and profitability. No quantitative revenue or earnings guidance is provided in the filing. Planned 2023 capital expenditures are estimated at $30 million to $40 million. Management reported that it did not anticipate significant 2023 clinical revenue changes from known legislation or rulemaking, while noting uncertainty around future regulation of laboratory-developed tests.
- Regulatory investigation: The company voluntarily reported an internal investigation concerning certain consulting and service agreements to HHS OIG in November 2021. DOJ joined the investigation in June 2022. A reserve of $11.2 million was recorded for the estimated minimum probable loss; the company could not estimate a possible loss range above that amount. Additional reserves, penalties, repayments, or operating restrictions could result.
- Litigation: Inivata subsidiaries face two Natera patent-infringement suits concerning InVisionFirst-Lung and RaDaR. A purported shareholder class action filed in December 2022 alleges securities-law violations. The company says outcomes were not estimable or probable at filing and asserts it has defenses.
- Business and financial risks: The filing highlights reimbursement and payer-policy changes, competition and pricing pressure, capacity and staffing constraints, supply-chain delays, dependence on shipping services, cybersecurity and privacy obligations, and possible Pharma contract delays or cancellations. Convertible notes require future repayment and may create cash, refinancing, or dilution risks.
- Goodwill and estimates: Goodwill was $522.8 million. After indicators of potential impairment in 2022, including leadership changes and a lower share price, the company’s quantitative assessment found no impairment. Fair-value estimates remain sensitive to projected revenue, margins, and discount rates.
The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. Management and the auditor concluded that internal controls were effective as of December 31, 2022.
Investor verification priorities
- Track whether revenue growth translates into improved gross margin, operating results, and operating cash flow.
- Assess execution and costs of the restructuring plan, including the expected additional $5.0 million charge and 2023 capital spending.
- Monitor the OIG/DOJ investigation, adequacy of the $11.2 million reserve, and any related repayment, penalty, or compliance requirements.
- Follow outcomes and potential financial effects of the Natera patent cases and shareholder class action.
- Review liquidity and debt service needs as the 2025 and 2028 convertible notes approach maturity, alongside cash and marketable securities.
- Evaluate reimbursement developments, LDT regulation, and the commercial adoption and economics of RaDaR and other new tests.